tetano
Editor, Senior Moderator
Sci Rep
. 2023 Aug 7;13(1):12784.
doi: 10.1038/s41598-023-39681-7. Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
Dateng Li[SUP] #[/SUP][SUP] 1 [/SUP], Meng Xu[SUP] #[/SUP][SUP] 1 [/SUP], Andrea T Hooper[SUP] 1 [/SUP], Diana Rofail[SUP] 1 [/SUP], Kusha A Mohammadi[SUP] 1 [/SUP], Yiziying Chen[SUP] 1 [/SUP], Shazia Ali[SUP] 1 [/SUP], Thomas Norton[SUP] 1 [/SUP], David M Weinreich[SUP] 1 [/SUP], Bret J Musser[SUP] 1 [/SUP], Jennifer D Hamilton[SUP] 1 [/SUP], Gregory P Geba[SUP] 2 [/SUP]
Affiliations
Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution of individual symptoms was assessed for resolution patterns across risk factors, and baseline SARS-CoV-2-specific antibody responses against S1 and N domains. CAS + IMD versus placebo provided statistically significant resolution for 17/23 symptoms, with greater response linked to absence of endogenous anti-SARS-CoV-2 immunoglobulin (Ig)G, IgA, or specific neutralizing antibodies at baseline, or high baseline viral load. Resolution of five key symptoms (onset days 3-5)-dyspnea, cough, feeling feverish, fatigue, and loss of appetite-independently correlated with reduced hospitalization and death (hazard ratio range: 0.31-0.56; P < 0.001-0.043), and was more rapid in CAS + IMD-treated patients lacking robust early antibody responses. Those who seroconverted late still benefited from treatment. Thus, highly neutralizing COVID-19-specific antibodies provided by CAS + IMD treatment accelerated key symptom resolution associated with hospitalization and death in those at high risk for severe disease as well as in those lacking early, endogenous neutralizing antibody responses.
. 2023 Aug 7;13(1):12784.
doi: 10.1038/s41598-023-39681-7. Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
Dateng Li[SUP] #[/SUP][SUP] 1 [/SUP], Meng Xu[SUP] #[/SUP][SUP] 1 [/SUP], Andrea T Hooper[SUP] 1 [/SUP], Diana Rofail[SUP] 1 [/SUP], Kusha A Mohammadi[SUP] 1 [/SUP], Yiziying Chen[SUP] 1 [/SUP], Shazia Ali[SUP] 1 [/SUP], Thomas Norton[SUP] 1 [/SUP], David M Weinreich[SUP] 1 [/SUP], Bret J Musser[SUP] 1 [/SUP], Jennifer D Hamilton[SUP] 1 [/SUP], Gregory P Geba[SUP] 2 [/SUP]
Affiliations
- PMID: 37550377
- DOI: 10.1038/s41598-023-39681-7
Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution of individual symptoms was assessed for resolution patterns across risk factors, and baseline SARS-CoV-2-specific antibody responses against S1 and N domains. CAS + IMD versus placebo provided statistically significant resolution for 17/23 symptoms, with greater response linked to absence of endogenous anti-SARS-CoV-2 immunoglobulin (Ig)G, IgA, or specific neutralizing antibodies at baseline, or high baseline viral load. Resolution of five key symptoms (onset days 3-5)-dyspnea, cough, feeling feverish, fatigue, and loss of appetite-independently correlated with reduced hospitalization and death (hazard ratio range: 0.31-0.56; P < 0.001-0.043), and was more rapid in CAS + IMD-treated patients lacking robust early antibody responses. Those who seroconverted late still benefited from treatment. Thus, highly neutralizing COVID-19-specific antibodies provided by CAS + IMD treatment accelerated key symptom resolution associated with hospitalization and death in those at high risk for severe disease as well as in those lacking early, endogenous neutralizing antibody responses.